E

EQT Life Sciences portfolio

EQT Life Sciences has 7 portfolio companies on record at Recent Funding, with 2 investments in the last 12 months. It led 2 of the 6 rounds it joined. Its most recent investment on record is Tenpoint Therapeutics's $235M Series B+ round in January 2026, alongside Janus Henderson Investors, Hillhouse Investment, EQT and 6 others. By category, its portfolio leans toward Health and bio (7) and Logistics and mobility (1). It has co-invested with RA Capital Management, Sixty Degree Capital and Asabys Partners, most often RA Capital Management (2 rounds).

What EQT Life Sciences invests in

• Health and bio · 7 · 100%
• Logistics and mobility · 1 · 14%

EQT Life Sciences recent investments

Company	Round	Date	Alongside
TTenpoint Therapeutics	Series B+ · $235M	Jan 29, 2026	Janus Henderson Investors (lead), Hillhouse Investment (lead), EQT (lead) +6
KKinaset Therapeutics	Series B+ · $103M	Jan 9, 2026	Willett Advisors LLC, Vivo Capital, Sixty Degree Capital +6
SSplice Bio	Series B+ · $140M · lead	Jun 11, 2025	Ysios Capital, UCB Ventures, Sanofi Ventures (lead) +5
TTubulis	Series B+ · $138M · lead	Mar 14, 2024	Seventure Partners, OCCIDENT, Nextech Invest (lead) +6
AAgomab Therapeutics	Series B+ · $95.45M	Oct 11, 2023	Walleye Capital, Redmile Group, Pontifax +6
TT-Knife	Series B+ · $110M	Aug 2, 2021	Fidelity (lead), Versant Ventures, Sixty Degree Capital +5

How EQT Life Sciences invests

Share is of the 6 rounds on Recent Funding that name EQT Life Sciences. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

EQT Life Sciences portfolio companies

• TTenpoint Therapeutics$235MSeries B+ · Jan 2026
• KKinaset Therapeutics$103MSeries B+ · Jan 2026
• SSplice Bio$140MSeries B+ · Jun 2025
• TTubulis$138MSeries B+ · Mar 2024
• AAgomab Therapeutics$95.45MSeries B+ · Oct 2023
• TT-Knife$110MSeries B+ · Aug 2021
• NNoema Pharmabacker

Company	Round with EQT Life Sciences	Total raised	Latest raise
TTenpoint Therapeutics Health and bio	Jan 29, 2026 Series B+ · $235M	$235M	Jun 12, 2026 Series A
KKinaset Therapeutics Health and bio	Jan 9, 2026 Series B+ · $103M	$143M	Jan 9, 2026 Series B+
SSplice Bio Health and bio	Jun 11, 2025 Series B+ · $140M · lead	$197M	Jun 11, 2025 Series B+
TTubulis Health and bio	Mar 14, 2024 Series B+ · $138M · lead	$573M	Oct 16, 2025 Series B+
AAgomab Therapeutics Health and bio	Oct 11, 2023 Series B+ · $95.45M	$193.45M	Oct 11, 2023 Series B+
TT-Knife Health and bio	Aug 2, 2021 Series B+ · $110M	$188M	Aug 2, 2021 Series B+
NNoema Pharma Health and bio	backer	$171M	Nov 4, 2025 Series B+

Most frequent co-investors

• RRA Capital Management2 shared rounds · last Jan 9, 2026
• SSixty Degree Capital2 shared rounds · last Jan 9, 2026
• AAsabys Partners2 shared rounds · last Jun 11, 2025
• FFidelity2 shared rounds · last Oct 11, 2023
• JJanus Henderson Investors1 shared round · last Jan 29, 2026
• BBritish Business Bank1 shared round · last Jan 29, 2026
• FF-Prime Capital1 shared round · last Jan 29, 2026
• EEQT1 shared round · last Jan 29, 2026
• EEight Roads Ventures1 shared round · last Jan 29, 2026
• SSofinnova Partners1 shared round · last Jan 29, 2026
• QQiming Venture Partners USA1 shared round · last Jan 29, 2026
• HHillhouse Investment1 shared round · last Jan 29, 2026

Similar investors

• KKorea Investment Partners7 companies · 4 deals in 12 mo
• MMarch Capital7 companies · 3 deals in 12 mo
• NNight Capital7 companies · 3 deals in 12 mo
• EElaia7 companies · 2 deals in 12 mo
• MMoore Strategic Ventures7 companies · 2 deals in 12 mo
• MMorningside7 companies · 2 deals in 12 mo

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

Portfolio companies are the companies on Recent Funding with a round that lists EQT Life Sciences, which is a subset of its real portfolio. API: /api/v1/investors/eqt-life-sciences (get a free API key). More: the most active VC firms and new venture capital funds.